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PET/CT is a relatively new imaging technology, whose undoubted advantages are valuable
in clinical oncology as well as in all fields of diagnosis, staging, and treatment. The hardware
combination of anatomy and function has been the true evolution in imaging. PET using 18F-
fluorodeoxyglucose (FDG†) is increasingly used for the staging of solid malignancies, includ-
ing colon, lung, etc., but anatomic information is limited. Integrated PET/CT enables optimal
anatomic delineation of PET findings and identification of FDG-negative lesions on com-
puted tomography (CT) images and might improve preoperative staging. However, contro-
versy still exists in relation to the application of PET/CT in clinical practice, mainly because
of its high cost. It is evident that apart from additional costs, potential savings also are as-
sociated with PET/CT as a result of avoiding additional imaging examinations or invasive
procedures and by helping clinicians make the optimum treatment decisions. The authors
review the literature on the role of PET/CT in management of various tumors and discuss
the medicoeconomic usefulness.
INTRODUCTION
For the past decades, Computed To-
mography (CT) has been the gold standard
imaging method in oncology. It has been
used for initial staging, tumor evaluation
after treatment, and follow-up of patients
with cancer. The method depicts intricate
morphological changes with the use of in-
travascular contrast, abnormal contrast en-
hancement, and blood flow due to
pathological circumstances. However, this
conventional imaging technique is not al-
ways efficient in the differentiation be-
tween benign and malignant lesions [1,2].
Positron EmissionTomography (PET),
on the other hand, is a non-invasive molec-
ular imaging technique that uses various ra-
diolabeled compounds and visualizes
metabolic differences between tissues, thus
depicting the functional status of a suspi-
cious lesion. PET was developed in the
early 1970s and was approved in the United
States for limited use in the oncological
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ment of this method was based on the obser-
vation that malignant cells are associated
with an increased glycolytic rate and in-
creased cellular glucose uptake. In order to
visualize this biochemical procedure, radio-
labeled 18F-fluorodeoxyglucose (18F-FDG)
is used. FDG is a glucose analogue that has
the same cellular uptake as glucose but is
metabolically trapped within the cell after
enzymatic phosphorylation to FDG-6-
phosphate. Therefore, FDG can be used to
quantify glucose metabolic rates [5,6].
One of the most important limitations of
PET is that most anatomic structures are
poorly depicted, if not completely absent,
thus making it difficult to localize tumor le-
sions precisely. Furthermore, FDG accumu-
lates in various normal tissues, such as the
brain,muscles,salivaryglands,thyroidgland,
myocardium, gastrointestinal tract, and the
urinarytract.Itis,therefore,attimesdifficult
to interpret the images when the neoplasm is
located near an organ with physiological
FDG uptake [1,7,8]. It is also challenging to
differentiate lesions due to malignancy from
lesions due to inflammation in which FDG
accumulation is equally intense due to in-
creasedglucosemetabolicrates.Finally,FDG
uptake is variable in some types of cancer,
thus limiting the diagnostic value of PET [9-
11]. For example, most well-differentiated,
hypocellular, and mucous-producing tumors
demonstrate low uptake of the tracer [12].
Consequently, FDG-PET could not be
used as an independent imaging method in
oncology. In order to interpret the PET im-
ages correctly, the clinician has to correlate
them with images of a more morphologi-
cally oriented imaging technique.
DEVELOPMENT OF PET/CT
In oncological imaging, the goals are le-
sion detection and localization ― including
anatomicalcorrelationwithstructuressuchas
vessels ― lesion characterization, proper
staging,andtreatmentsuccess.Someofthese
goals require precise anatomical imaging,
whereasothersdemandmoleculartechniques
[5-11].Itwas,therefore,easilyacknowledged
that FDG-PET and CT are complementary,
and the employment of the two is imperative
intheoncologicalclinicalpractice.Visualim-
position of the images was often considered
sufficient, but the development of software
fusionalgorithmsprovidedmoreaccuratelo-
calization [13].
However, fusion was difficult and
sometimes outright unsuccessful when it in-
volved structures outside the brain: Errors
were observed with deformable soft-tissue
organs as well as with organs in which time
difference mattered between imaging proce-
dures as seen with the dynamic motion of
the gastrointestinal organs [1,2,9,13-15].
The need for data hardware, rather than
software, fusion of the functional PET with
the morphologically oriented CT remained
apparent. In 1998, Townsend and his col-
leaguesintroducedthefirstPET/CTprototype
― a single integrated device ― combining
the two techniques in order to minimize tem-
poral and spatial differences [5]. Imaging
manufacturers made PET/CT scanners com-
merciallyavailablein2001[7].Themostim-
portantadvantageofthishardwarefusionwas
thatitmadeimagesavailablefromonedevice
in a single patient positioning. Since the pa-
tient remains on the same bed for both scans,
spatial and temporal differences are elimi-
nated [16]. Internal organ movement is mini-
mal since both scans are acquired roughly in
sync. CTis used for attenuation correction of
PET, and the imposed anatomical and func-
tional images are available immediately after
the scan for corroboration [5,17-19].
INDICATIONS IN ONCOLOGY
Currently, PET/CThas mostly found its
application in the clinical practices of oncol-
ogy (97 percent) and much less in infection
(2 percent) and cardiology (1 percent). The
primary areas of interest are diagnosis, stag-
ing, treatment-effectiveness monitoring, and
radiotherapeutic planning ― practically all
fields of tumor management [20,21].
Diagnosis
In the area of diagnosis, the PET/CT is
not frequently used. It is mostly indicated in
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― especially those that are not amenable to
percutaneous biopsy ― and the assessment
of lymphadenopathy [2,20,21]. It also may
be helpful in cases of abnormalities that are
“intermediate,” according to imaging crite-
ria and the patient, if the clinician is hesitant
to proceed with an invasive procedure or in
cases of suspicious lesions examined
pathoanatomically but with no definite diag-
nosis. Furthermore, PET/CTmay be used in
cases of pyrexia of unknown origin and sus-
pected paraneoplastic syndromes [22,23].
Staging and Restaging
When PET/CTwas first introduced, the
oncological indications approved by
Medicare included staging and restaging of
non-small cell lung cancer, esophageal can-
cer, colorectal cancer, pancreatic cancer,
ovarian cancer, head and neck cancer, breast
cancer, melanoma, and lymphoma. In 2003,
the additional indications of monitoring
breast and thyroid cancer were approved,
and it is expected that more indications will
be approved in the future [3,24,25].
Poor co-registration of PETand CTim-
ages due to motion of the diaphragm also
may lead to inaccurate interpretation of
chest tumors. However, recent data have
shown that integrated PET/CT images, re-
garding tumor staging, are superior to PET
images alone and PET and CT images
viewed side by side. Lardinois et al. were the
first who found a diagnostic advantage for
PET/CTover all the other methods in regard
to the determination of T and N stage. In re-
gard to non-small cell lung cancer
(NSCLC), PET/CT scans have proven to be
statistically more accurate than any other
method, as far as tumor staging is con-
cerned. As a result of the exact correlation
between anatomy and functional disorder,
focal chest wall infiltration, mediastinal in-
vasion (with the ability to distinguish be-
tween contiguity of tumor and mediastinum
from the direct invasion of the walls of the
mediastinum), and differentiation of tumor
from atelectasis have largely improved with
PET/CT[26-28].Although mediastinoscopy
remains the standard procedure for mediasti-
nal nodal staging, PET/CT has proven to be
a very sensitive noninvasive staging tech-
nique and may even determine the exact lo-
cation of a solitary lymph node, thus
concluding the precise classification as N1
or N2 [29]. Unsuspected extra thoracic soft
tissue or skeletal metastases also may be re-
vealed by PET/CT in cases where other im-
aging methods failed to demonstrate distant
metastasis [30]. Adrenal enlargement is
often a diagnostic problem that can be
solved with PET/CT. One limitation is cere-
bral metastasis, because the brain shows the
highest normal FDG accumulation. Overall,
it has been demonstrated that PET/CT is an
important feature for precise NSCLC stag-
ing. The extent of tumor spread is the pri-
mary factor that determines whether the
patient will undergo surgery or will be of-
fered a non-surgical treatment. Studies have
concluded that PET/CT resulted in an alter-
ation of treatment management in up to 30
percent of NSCLC patients [20,27,30-34].
The value of PET/CTin patients under-
going restaging after treatment is equally ap-
parent. Recurrence, whether local,
intrathoracic, or distant, is successfully de-
tected by PET/CT. Furthermore, with this
imaging modality, it is now possible to dis-
tinguish between malignancy and post-ther-
apeutic change [33]. Surgical resection may
cause scarring and anatomical distortion,
which can conceal early changes caused by
tumor spread. Likewise, radiation-induced
pneumonitis may provoke mass-like
changes. PET/CThelps in the differential di-
agnosis by enabling the exact localization of
increased FDG uptake [20,22,35,36].
Similarly as seen in lung cancer,
PET/CTcan also help in the management of
malignant pleural mesothelioma. In this
case, PET/CT is useful in documenting the
extent of pleural effusion, the possible in-
volvement of the lymph nodes, and the in-
filtration of the pulmonary parenchyma as
well as the thoracic wall. It also has an im-
portant part in the diagnosis of distant
metastases and the assessment treatment re-
sponse [20,37].
Few studies have been performed to de-
termine the role of PET/CTin breast cancer.
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cancer if diagnosed at an early stage, pre-op-
erative staging is extremely important as it
influences the choice of surgical treatment
[35]. Sensitivity, specificity, and accuracy of
PET/CT for the diagnosis of the primary
tumor and detection of axillary lymph node
metastasis is limited [38,39]. However, this
method seems to be superior to mammogra-
phy, ultrasound, or PET alone.The sensitiv-
ity of PET/CT to diagnose micrometastases
is limited, and therefore restricting, as far as
the initial staging of breast cancer and axil-
lary node infiltration are concerned. Further-
more, the histological characteristics of the
tumor may affect FDG-PET imaging
enough to fail to visualize the primary tumor
[22]. In clinical practice, PET and PET/CT
are useful in restaging and demonstration of
distant metastases. The increased localiza-
tion accuracy of PET/CT results in the de-
tection of metastases in the internal
mammary node chain, which have been pre-
viously disregarded as nonspecific with PET
[40]. PET/CT also may be helpful in the
evaluation of treatment. However, in the
screening and diagnosis of primary breast
tumors, the high cost of PET/CT does not
allow wide application [20,25,39].
As far as esophageal and gastric carci-
nomas are concerned, PET/CT has limited
accuracy in the identification of the primary
tumor. This is because a variety of benign
conditions of the esophagus, such as Barrett
esophagus, also lead to high FDG uptake
[20,25]. Furthermore, focal areas of brown
fat, asymmetric uptake in the vocal cords,
and vessel atherosclerosis may lead to false
positive results, although these areas are
generally better differentiated from areas of
esophageal uptake on PET/CT, rather than
on PET images [41,42]. False negative
FDG-PET images in regard to the identifi-
cation of primary tumors have been re-
ported up to 20 percent.As far as staging is
concerned, many studies have been carried
out, and the results indicate a major benefit
of PET/CT as opposed to FDG-PET in the
determination of M stage. Tumor size and
local-regional lymph node involvement can
be evaluated with a sensitivity of only 30
percent by PET, while PET/CT has slightly
improved this percentage [42]. On the other
hand, the detection of gastric cancer de-
pends on the histological type.After the di-
agnosis has been made, PET/CT can be
used to determine the depth of invasion of
the primary tumor and evaluate the nodal
spread of the disease, including distant
metastasis. The utility of this technique in
esophageal cancer is most evident in the
evaluation of the response to chemotherapy.
Patients responding to treatment had a sig-
nificant reduction of tumor FDG accumula-
tion in relation to those not responding
[20,41,43-45].
Although PET images alone are diffi-
cult to interpret in the evaluation of abdom-
inal and pelvic tumors ― due to the absence
of anatomical landmarks and the nonspecific
FDG uptake in the gastrointestinal tract ―
PET/CT fusion images may be of great im-
portance. PET/CT was more accurate than
PET alone in staging and restaging of col-
orectal cancer [1,22,46]. It also has proved
to be equally effective as a contrast-en-
hanced CT in detecting distant metastasis,
but more sensitive in the detection of local
recurrence and liver metastasis in patients
with prior hepatectomy. PET/CTalso can be
useful in patients with liver lesions that can-
not be clearly characterized by CT [47,48].
Early detection of liver metastases may af-
fect patient management, providing the op-
portunity for neoadjuvant chemotherapy and
tumor resection. It is important to point out
that in several trials, after PET/CT imaging
was performed, the treatment strategy was
altered in 20 percent to 35 percent of pa-
tients [24,49-50].
Stromal tumors of the gastrointestinal
tract may show heterogeneity in FDG accu-
mulation between different lesions of the
same patient. PET/CTis, therefore, comple-
mentary to CT in terms of staging and de-
tection of metastasis. There are studies,
however, that have confirmed its superiority
in assessing response to treatment with ima-
tinib. Patients without FDG uptake and after
the initiation of therapy have better progno-
sis than patients with residual activity
[1,20,51,52].
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cornerstone of diagnosis and staging of pan-
creatic cancer. However, differentiation of
masses such as chronic pancreatitis and car-
cinoma remains difficult with these modali-
ties [22,25,50]. In their study, Heinrich et al.
showed that PET/CT in pancreatic cancer is
equally sensitive as CT, but has an increased
specificity. PET/CT showed a positive and
negative predictive value of 91 percent and
64 percent, respectively [53]. It also proved
to be more effective than standard staging in
detecting distant metastasis, thus altering the
therapeutic plan in 16 percent of patients. In
addition, PET/CT can guide biopsies to the
most active lesion, allowing for a more pre-
cise diagnosis [20,22].
Little evidence from selected case re-
ports has shown superiority of FDG-PET in
imaging of ovarian and fallopian tube carci-
noma. Malignant lesions often accumulate
FDG but cannot be detected by CT. Exact
localization of the neoplasm in order to de-
fine the therapeutic procedure is crucial and
can be achieved with fusion PETand CTim-
ages [54]. PET/CT also was effective in
demonstrating peritoneal disease specificity
and sensitivity much higher than those of CT
alone.The sensitivity of PET/CTfor staging
and restaging of endometrial and cervical
cancer has been compared to conventional
imaging, and the results were very encour-
aging [55-57].
Loco-regional evaluation of head and
neck cancer is extremely complex by defi-
nition.The limitations are due to the normal
or questionable size of the lymph nodes,
which with the conventional imaging tech-
niques cannot be classified as either normal
or pathologic [24]. FDG-PET, on the other
hand, is not efficient enough because of
physiologic FDG uptake in muscular, lym-
phoid, glandular and fatty tissue, and proxi-
mal to metal dental work. The problem is
even more serious in patients who have un-
dergone surgery [58,59]. Thus, interpreta-
tion of both anatomical and functional
images is of great importance. Even though
data on the use of PET/CT is locoregional,
staging of head and neck cancer is limited.
This modality seems to offer an easier dis-
tinction between lymph nodes of normal
FDG uptake and those that are abnormal
which may have normal sizes but actually
contain malignant cells.Therefore, it is more
accurately possible to be upstaged to N1
[60-63].Although distant metastasis is infre-
quent in head and neck carcinomas, PET/CT
is helpful in their identification. Relevant tu-
mors, such as lung and esophageal carci-
noma and precancerous or cancerous lesions
in the large bowel, may be present in pa-
tients with head and neck carcinomas and
are readily defined by PET/CT [64].All the
information acquired is used in order to give
the patient the treatment indicated. In most
cases, extensive surgery and radiotherapy
are used as standard treatment procedures.
As a result, the anatomy of the site is largely
altered, while persistent sterile inflammation
is often present. PET/CTcannot always dis-
tinguish between inflammation and malig-
nancy, but it can be used in order to identify
the best biopsy site, if biopsy is necessary
[61-63].
Most well-differentiated thyroid malig-
nancies show high iodine uptake, but are not
FDG avid. In cases of dedifferentiation,
these more aggressive tumor cells lose their
ability to accumulate iodine. If thyroid can-
cer is iodine negative, other imaging meth-
ods are required for staging and restaging
[25,30]. FDG-PET has proven valuable in
this case. It allows for precise metastatic lo-
calization and allows differentiation be-
tween tumor and scar tissue, thus preventing
unnecessary interventions [65,66]. In one
study, PET/CTfindings altered the treatment
plan in 67 percent of patients with thyroid
cancer. Most of these patients had markedly
elevated serum thyroglobulin levels and
negative 123I scans. No false positive scans
occurred [25]. In patients with suspected dif-
ferentiated but iodine negative tumors,
PET/CTproved to be more accurate than CT
for the detection of disease, with a sensitiv-
ity of 93 percent [67].
Malignant melanoma and its metastases
are highly FDG-accumulative. PET/CT is
not useful for initial staging or for patients
with early disease with no nodal or distant
metastasis [68]. Even though the primary le-
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technique is not currently used to determine
theTstage. Several studies and meta-analy-
ses report that the sensitivity and specificity
of FDG/PET in detecting recurrent
melanoma ranges from 70 percent to 100
percent. With the exception of the brain,
FDG-PET can successfully locate metas-
tases and micrometastases at unusual sites
that may be missed with conventional imag-
ing modalities. PET/CT will determine the
exact location of metastasis. Surgical resec-
tion is the treatment of choice in the case of
regional lymph node spread or a single dis-
tant metastasis [50,69,70]. However, only
palliative symptomatic treatment is indi-
cated in the presence of distant lesions. Un-
expected findings in PET/CT have been
reported in 15 percent of cases. Therefore,
PET/CTshould be performed not only in pa-
tients scheduled for surgery to exclude oc-
cult metastases, but also to achieve the most
minimally invasive excision possible
[50,71].
Both Hodgkin and non-Hodgkin lym-
phoma usually show high FDG accumula-
tion. FDG-PET, where available, already has
replaced gallium scan in the detection of
lymphatic lesions. The assessment of lym-
phoma distribution is of great importance for
the choice of the optimal treatment [72,73].
Non-enhanced CT is very accurate in defin-
ing lymphadenopathy, based on anatomical
criteria. However, nodes of normal size may
contain disease. PET is the indicated imag-
ing method to determine the presence or ab-
sence of disease. However, non-Hodgkin’s
disease is often extra nodal and may occur in
almost any site of the human body. PET/CT
is the indicated modality to provide confi-
dence in identifying and localizing the le-
sion. It also may be helpful on occasion
when no CTfindings correlate with the PET
abnormality. Biopsy sites, when needed, can
also be determined by PET/CT [50]. While
lymphomatous masses usually respond dra-
matically to treatment, residual masses are
often present after therapy. It is of great im-
portance to distinguish viable lymphoma
from necrotic tissue and fibrosis. Morpho-
logical imaging methods are not at all effec-
tive for this purpose, as opposed to PET/CT.
It is very interesting to mention that in the
case of a low-grade lymphoma, an unex-
pected increase in FDG accumulation in any
or all known parts of the disease during fol-
low-up suggests transformation to a higher
grade lymphoma [74-77].
PET/CT, by searching the whole body
for anatomic and metabolic alterations, may
lead the physician to incidental findings of
unsuspected malignancies. Normal struc-
tures show 18F-FDG uptake, which, in con-
trast with the uptake of pathologic tissues, is
usually symmetric. In the study by Osman
et al., non-contrast enhanced PET/CT re-
vealed unexpected lesions in 3 percent of pa-
tients [78]. Other studies reported
unsuspected hypermetabolic lesions, which
were confirmed as malignant in at least 1,2
percent of patients [25,79].
It is conceivable that PET/CT could be
used in the management of cancer in regard
to the detection of occult metastasis. In some
cases, during follow-up after treatment,
tumor markers may be elevated, but no site
of residual disease can be detected by con-
ventional imaging. PET/CT may detect and
localize successfully the malignant lesion
with increased FDG uptake.
Treatment monitoring
It has been discussed previously that
PET/CT can be very effective in treatment
response assessment due to its characteris-
tics of functional or metabolic imaging.The
assessment of residual tumor after a course
of therapy (surgery, chemotherapy, or irra-
diation) is usually made by conventional
anatomical imaging procedures, although
FDG-PET is sometimes used in clinical
practice during restaging. However, meta-
bolic changes within the tumor have been
documented very early after treatment. For
example, FDG uptake reduction in patients
with lymphoma can be monitored within a
few hours after treatment [37,38]. Evidently,
a metabolic response, reflecting the malig-
nant cells’ viability, may precede an alter-
ation in the size of a tumor lesion. As a
result, reduced FDG uptake may demon-
strate treatment effectiveness much earlier
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chemotherapy infusion. Studies demon-
strated that the decrease of FDG uptake after
a single infusion of chemotherapy was a pre-
dictor of eventual response to this regimen
[80]. Similarly, no decrease of tumor FDG
uptake after the first infusion was a predictor
of non-response. Morphological changes in
the tumor usually occur after a certain inter-
val following therapy. As a result, multiple
doses of antineoplastic agents are adminis-
tered, even if they are ineffective. The early
identification of response via PET/CThelps
the clinician decide whether the same treat-
ment should be continued or another alter-
native is required [20,22]. Clinical studies
have demonstrated that PETcan readily pre-
dict response to chemotherapy in cases of
breast cancer, lymphoma, NSCLC, head and
neck, esophageal, and gastric cancer, as well
as liver metastasis [81-83]. Early decrease
of FDG uptake has been monitored and seen
in molecular targeted therapy (with ima-
tinib) and radiotherapy as well [84].
Radiotherapy planning
It is becoming obvious that PET/CT
will have an important role in radiotherapy
planning in the future. Successful radiation
planning requires accurate evaluation of the
extent of the disease. Traditionally, this is
performed with a CTscan prior to radiother-
apy simulation [22,25]. The anatomical in-
formation is used in order to determine the
radiation boundaries. However, the micro-
scopic extension of the tumor around the
gross tumor volume (GVT) cannot be deter-
mined by CT. In order to overcome this
problem, the volume treated is much greater
than the gross tumor volume. On the other
hand, precise and accurate localization of RT
targeted to GTVis critical for optimizing the
therapeutic ratio [85-88]. By measuring the
metabolically active tumor volume, PET on
its own provides functional data that can be
used in order to improve tumor coverage, in-
cluding the involved lymph nodes, and thus
reduce normal tissue exposure [89]. Feasi-
bility studies have shown that a PET/CT
scan may provide valuable information for
accurate staging and decision making in the
field of radiotherapy, changing treatment
strategies in about 25 percent of patients.
Treatment changes include prevention of in-
appropriate radiotherapy, changes in radia-
tion dose or target volume, and changes in
planning regarding curative or palliative ra-
diation therapy. Data from a CTmay be used
for volume planning and delineating tumor
margins; whereas, PET differentiates viable
from non-viable and aggressive from non-
aggressive lesions. In NSCLC, for example,
PET/CT helps distinguish tumor involve-
ment from atelectasis. By demonstrating the
most active tumor lesions, PET/CT may
play a role by adjusting regional radiation
dosages accordingly [86,89-92].
The evaluation of local response after
RT with conventional imaging may be of
limited accuracy, because the presence of fi-
brosis, atelectasis, or radiation-induced
pneumonitis may be falsely interpreted as
disease. Inflammed lymph nodes also may
be misinterpreted [88]. Even though RT-in-
duced inflammation accumulates 18F-FDG,
there is data suggesting that a viable tumor
shows higher uptake, thus making the dif-
ferentiation feasible. The optimal timing to
perform PET/CT in order to minimize both
false positive (due to inflammation) and
false negative results (in case residual dis-
ease has not yet reached the threshold of res-
olution by PET) has not yet been
determined. All the above suggest that
PET/CTcould successfully become the first
imaging study for a more rational approach
to radiation treatment planning for cancer
patients [22,86,87,90].
COST CONSIDERATIONS
PET/CThas only been available in clin-
ical practice for approximately five years
and is expanding rapidly. The hardware fu-
sion of the morphological CT-acquired data
and the metabolic PETimages has proven to
be more efficient and less time consuming
than visual or software fusion, and no extra
personnel needs to be involved [1].The con-
temporary acquisition of images reduces
problems due to misalignment or possible
change of the disease in the interval between
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pears that PET/CTis more accurate in tumor
localization and cancer staging as compared
to PET alone, CT alone, or CT plus PET
[11]. Several studies have reported a change
in the management of up to 18 percent to 25
percent of cases after PET/CTscan [1,11,93-
95].
Cost calculations show that there are
savings from the integration of PET and CT
in one system. First, there are several occa-
sions in which FDG-PET leads to equivocal
findings, and follow-up imaging studies
(usually CT scans) are required. If patients
undergo bothexaminationsinonesession,in
addition to having more accurate results,
costs will be lower [1,3]. Second, PET is a
quite lengthy procedure, as it requires both
emission and transmission scans. Image fu-
sion between PET and CT has resulted in an
average time savings of 20 to 30 minutes per
patient. In this case, transmission scans are
notrequiredbecausetheCTdataareusedfor
attenuation correction. It has been estimated
that patient output has increased by approx-
imately 40 percent. Furthermore, a shorter
scanningtimeresultsinmoreefficientuseof
FDG, since it decays rapidly due to its short
half-life.Consequently,anincreaseinpatient
throughput and a simultaneous decrease in
FDG requirements for the same number of
patients may bring additional income to the
institution. Even with fewer FDG require-
ments,abetterpricefortheradiopharmaceu-
tical is negotiable, as the examination
sequence gets faster [1,11,93,96].
In cases of biopsy sampling, PET/CTis
the most adequate method to demonstrate
the area that is most likely to be of diagnos-
tic value. This avoids unnecessary invasive
procedures [1,3,9,11]. With regard to surgi-
cal treatment, the method contributes to ac-
curate decision making. There is now
substantial evidence that PET/CT is an ex-
tremely sensitive imaging modality in the
detection of malignant tissues and that it
presents a higher specificity than PETalone,
which is the main reason for fewer equivocal
scans and better diagnostic results. Precision
in staging may be prohibitive of surgical ex-
cision. In most cases, the patient is upstaged
by PET/CT[20,53]. Considering the median
length of pre- and post-operative hospital
stays (including intensive care unit costs
when necessary), the cost of surgical resec-
tions and biopsies, and the cost of PET/CT
scan, the avoidance of surgery was found
overall to be cost beneficial [3,20]. More
specifically, in the Heinrich et al. trial, pa-
tients with pancreatic tumors underwent
PET/CTscan for disease staging. Metastases
were found in 16 percent of patients with
cancer initially deemed resectable, leading
to different management and cost savings of
$1,066 per patient [53]. An estimated cost
for a Whipple procedure is in the range of
$35,000 to $40,000 in the United States
[97,98]. The expenses related to a hospital
stay for 12 to 20 days in the United States is
approximately $34,350 [84,85]. Neither
shortening the length of the hospital stay nor
the use of CT guided FNA and surgical as-
sessment of metastasis (by a thoracoscopic
or laparoscopic approach) would reverse the
cost effectiveness of PET/CT [97,98].
Likewise, radiotherapy and chemother-
apystrategiesalsocanbeadjustedaccordingto
staging, therapy-response evaluation, and
restaging. The potential of early response de-
tection with PET/CT helps avoid possible in-
effective and expensive drugs, thereby
tailoring treatment for each individual patient
[1,3,20,53,93]. Use of PET/CT scan in col-
orectalcancerandmelanomarestaginghasre-
sulted in a cost savings of approximately
$3,000and$4,400perpatient,respectively[3].
As PET/CT is the combination of PET
and CT, the major advantage of PET/CT is
the simultaneous availability of both func-
tional and anatomic information that facili-
tates an optimal fusion of both imaging
techniques. It is only by this improved imag-
ing fusion that FDG-positive findings, e.g.,
lymph node metastases, can be exactly iden-
tified.Though there is little data to comment
on cost, PET/CT scan detects unknown dis-
tant metastases and rules out suspicious le-
sions. Subsequently, surgery is performed in
cases in which respectability of tumors has
been confirmed.Thus, survival after surgery
is increased, and overall cost might be re-
duced [99].
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ical institutions need a PET/CTscanner. For
a cancer center, however, it could prove
quite valuable for patient management
[1,11,93]. Even in this setting, the need for a
PET/CT scanner would depend on the pa-
tient population served in this particular im-
aging center. Furthermore, the price of
PET/CT systems is likely to decline as the
method gains acceptance and continues to
spread [93].
FUTURE DEVELOPMENTS
PET/CT scan has the potential to
change clinical practice in numerous malig-
nancies. In prostate cancer, 18F-choline
seems to be a promising PET-tracer, useful
in the detection of disease recurrence and
bone metastases [100]. In sarcomas,
PET/CT can play a significant role in tumor
grading, staging, follow-up, and as a prog-
nostic factor [101]. PET/CTscan also seems
valuable as a response biomarker in order to
monitor not only cytotoxic but predomi-
nantly cytostatic cancer therapies [102]. As
targeted therapies are expensive and cause
considerable toxic adverse events, PET/CT
scan can be useful in identifying potential
responders [102]. It also offers original in-
formation concerning tumor biology [102].
Its indications in clinical oncology are con-
stantly being expanded in carcinomas such
as cervical [103], rectal [104], and lym-
phoma [105], and it constitutes the future
gold standard of care in lung cancer [106].
Development of new PET-tracers will in-
crease the number of indications of this mul-
timodality imaging technique. More
randomized multicenter clinical trials are
necessary in order to establish standardized
clinical algorithms and guidelines that in-
clude PET/CT scan.
CONCLUSION
PET/CT is a relatively new imaging
technology,whoseundoubtedadvantagesare
valuable in clinical oncology as well as in all
fields of diagnosis, staging, and treatment.
The hardware combination of anatomy and
function has been thetrueevolution in imag-
ing. PET/CT is a technique with high sensi-
tivity and specificity as far as malignant
lesionsareconcerned.Ithasdramaticallyim-
proved PET interpretation; it has reduced
equivocal interpretations; and it has in-
creased diagnostic accuracy. More accurate
staging, restaging, and prompt evaluation of
therapy may lead to appropriate changes in
patient management. However, controversy
still exists in relation to the application of
PET/CT in clinical practice, mainly because
of its expense. It is evident that apart from
additional costs, potential savings are asso-
ciated with PET/CT as a result of avoiding
additional imaging examinations or invasive
procedures and by helping clinicians make
the optimum treatment decisions. The evi-
dence continues to accumulate on its useful-
ness in clinical practice as a profound
imaging modality with expanding applica-
tions in a variety of oncological fields.
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